FK866 treatment does not affect the NAD+ mitochondrial pool; therefore, cancer cells may be more sensitive to FK866 than noncancerous cells.194 Moreover, FK866 cytotoxicity seems to be higher in tumors that express higher NAMPT levels and in cells that depend more on glycolysis.46 This evidence concerns the gene NAMPT and cancer.